SecBot SecBot
SECBOTREPLAY Home › Report › NUVL

NUVL · Nuvalent reported its 2025 financial results, highlighted a strong cash…

Nuvalent, Inc. · 8-K filed Feb 26, 2026 at 06:35 ET

At the news

BULLISHIMPACT 7/10

8-K filed Feb 26, 2026 at 06:35 ET

Nuvalent reported its 2025 financial results, highlighted a strong cash position of $1.4 billion with runway into 2029, and provided updates on its drug development pipeline. Key milestones include FDA acceptance of the NDA for zidesamtinib with a PDUFA date of September 18, 2026, and plans for neladalkib NDA submission in the first half of 2026. The company also completed a $500 million public offering in November 2025.

  • Cash, cash equivalents and marketable securities were $1.4 billion as of December 31, 2025
  • FDA accepted NDA for zidesamtinib with PDUFA target action date of September 18, 2026
  • Completed $500 million public offering of common stock in November 2025
  • R&D expenses were $307.0 million for full year 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access